Related Experiment Video
Updated: Dec 17, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
β-catenin promotes MTX resistance of leukemia cells by down-regulating FPGS expression via NF-κB
Shu-Guang Liu1, Zhi-Xia Yue1, Zhi-Gang Li1
1Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Key Laboratory of Major Diseases in Children, Ministry of Education, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, 56 Nanlishi Road, Beijing, 100045 China.
Background:
Aberrant activation of β-catenin has been shown to play important roles in the chemoresistance of acute lymphoblastic leukemia (ALL), but the involvement and mechanism of β-catenin in methotrexate (MTX) resistance is poorly understood. In the present study, we demonstrate a critical role of β-catenin-NF-κB-FPGS pathway in MTX resistance in the human T-lineage ALL cell lines.
Methods:
Lentivirus sh-β-catenin was used to silence the expression of β-catenin. Flow cytometry was performed to detect apoptosis after MTX treatment. Western blot, real-time PCR, Co-immunoprecipitation (Co-IP), Chromatin immunoprecipitation (ChIP), Re-ChIP, and Luciferase assay were utilized to investigate the relationship among β-catenin, nuclear factor (NF)-κB, and folypoly-γ-glutamate synthetase (FPGS).
Results:
Depletion of β-catenin significantly increased the cytotoxicity of MTX. At the molecular level, knockdown of β-catenin caused the increase of the protein level of FPGS and NF-κB p65. Furthermore, β-catenin complexed with NF-κB p65 and directly bound to the FPGS promoter to regulate its expression. In addition, β-catenin repression prolonged the protein turnover of FPGS.
Conclusions:
Taken together, our results demonstrate that β-catenin may contribute to MTX resistance in leukemia cells via the β-catenin-NF-κB-FPGS pathway, posing β-catenin as a potential target for combination treatments during ALL therapy.
Insights
Aberrant beta-catenin activation drives methotrexate resistance in acute lymphoblastic leukemia (ALL) by regulating the NF-kappaB-FPGS pathway. Targeting beta-catenin may enhance ALL treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aberrant beta-catenin activation is implicated in acute lymphoblastic leukemia (ALL) chemoresistance.
- The specific role and mechanism of beta-catenin in methotrexate (MTX) resistance remain unclear.
Purpose of the Study:
- To elucidate the role and mechanism of beta-catenin in MTX resistance in T-lineage ALL.
- To investigate the beta-catenin-NF-kappaB-FPGS pathway in MTX resistance.
Main Methods:
- Silencing beta-catenin using lentivirus sh-beta-catenin.
- Assessing apoptosis via flow cytometry post-MTX treatment.
- Employing Western blot, PCR, Co-IP, ChIP, Re-ChIP, and luciferase assays to analyze molecular interactions.
Main Results:
- Beta-catenin depletion significantly enhanced MTX cytotoxicity.
- Knockdown of beta-catenin increased protein levels of FPGS and NF-kappaB p65.
- Beta-catenin directly bound to the FPGS promoter, regulating its expression and prolonging FPGS protein turnover.
Conclusions:
- Beta-catenin contributes to MTX resistance in leukemia cells through the beta-catenin-NF-kappaB-FPGS pathway.
- Beta-catenin represents a potential therapeutic target for combination treatments in ALL.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Canonical Wnt Signaling Pathway
TGF - β Signaling Pathway
MAPK Signaling Cascades

